Evidence map›Paper›PMID 20686410›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2010

The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals.

Rachel J Gordon, Nancy Chez, Haomiao Jia, Barbara Zeller, Magda Sobieszczyk, Caitlin Brennan, Katherine B Hisert, Mei-Ho Lee, Peter Vavagiakis, Franklin D Lowy

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00801879 (Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00801879 phase4completednot on this map

Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection

TypeinterventionalSponsorColumbia UniversityRan2003 to 2006Enrolled100ConditionsStaphylococcus Aureus, HIV InfectionsArmsMupirocin calcium ointment, 2%, Placebo ointment
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Rachel J GordonDepartment of Medicine, Columbia University, New York, NY, USA. rj216@columbia.edu
Nancy Chez
Haomiao Jia
Barbara Zeller
Magda Sobieszczyk
Caitlin Brennan
Katherine B Hisert
Mei-Ho Lee
Peter Vavagiakis
Franklin D Lowy
Columbia University · USHanby Environmental (United States) · USNew York University · USPaññāsāstra University of Cambodia · KH

Funding

Social Networks of S. aureus Carriage Among Drug UsersR01DA015018 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOWY, FRANKLIN D · 2002 to 2006
$3.1M
Pathogenesis & epidemiology of S epidermidis ventricular assist device infectionsK08AI072043 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GORDON, RACHEL J. · 2007 to 2011
$622k
NIAID NIH HHS 5 T32 AI0149821-04NIAID NIH HHS K08 AI072043NIDA NIH HHS DA015018NIDA NIH HHS R01 DA015018PHS HHS 1K08A1072043-01A1
6 · The paper itself

Abstract

backgroundHIV-positive patients at HELP/PSI, Inc, an in-patient drug rehabilitation center, had a high baseline prevalence of Staphylococcus aureus colonization (49%) and incidence of infection (17%) in a previous year-long study.

methodsA randomized, double-blinded, placebo-controlled study was conducted to determine whether repeated nasal application of mupirocin ointment would decrease the odds of S. aureus nasal colonization in 100 HELP/PSI patients over an 8-month period. A 5-day course of study drug was given monthly, and colonization was assessed at baseline and 1 month after each treatment. S. aureus infection was a secondary outcome.

resultsIn repeated-measures analysis, mupirocin reduced the odds of monthly S. aureus nasal colonization by 83% compared with placebo [adjusted odds ratio (ORadj) = 0.17; P < 0.0001]. Subjects colonized at study entry had a 91% reduction in subsequent colonization (ORadj = 0.09; P < 0.0001). Mupirocin also suppressed S. aureus colonization in subjects not colonized at baseline (ORadj = 0.23; P = 0.006). There was no difference in infection rates between the mupirocin and placebo groups (hazard ratio = 0.49, P = 0.29).

conclusionsMonthly application of nasal mupirocin significantly decreased S. aureus colonization in HIV patients in residential drug rehabilitation. Monthly mupirocin application has a potential role in long-term care settings or in HIV-positive patients with high rates of S. aureus colonization and infection.

Indexed as

Administration, IntranasalAdultAIDS-Related Opportunistic InfectionsAnti-Bacterial AgentsDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMethicillin ResistanceMupirocinOintmentsStaphylococcal Skin InfectionsStaphylococcus aureusTreatment OutcomeAnti-Bacterial AgentsMupirocinOintments

Identifiers

PMID20686410
PMCPMC2974816
OpenAlexW1981604560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.